- Home
- WLGS vs JAGX Comparison
WLGS vs JAGX Comparison
Compare WLGS & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- JAGX
- Stock Information
- Founded
- WLGS 1981
- JAGX 2013
- Country
- WLGS Hong Kong
- JAGX United States
- Employees
- WLGS N/A
- JAGX N/A
- Industry
- WLGS Engineering & Construction
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- WLGS Consumer Discretionary
- JAGX Health Care
- Exchange
- WLGS Nasdaq
- JAGX Nasdaq
- Market Cap
- WLGS 4.2M
- JAGX 8.1M
- IPO Year
- WLGS 2023
- JAGX N/A
- Fundamental
- Price
- WLGS $0.17
- JAGX $8.51
- Analyst Decision
- WLGS
- JAGX
- Analyst Count
- WLGS 0
- JAGX 0
- Target Price
- WLGS N/A
- JAGX N/A
- AVG Volume (30 Days)
- WLGS 1.6M
- JAGX 246.2K
- Earning Date
- WLGS 05-20-2025
- JAGX 05-16-2025
- Dividend Yield
- WLGS N/A
- JAGX N/A
- EPS Growth
- WLGS N/A
- JAGX N/A
- EPS
- WLGS 0.02
- JAGX N/A
- Revenue
- WLGS $7,272,879.00
- JAGX $11,689,000.00
- Revenue This Year
- WLGS N/A
- JAGX $38.22
- Revenue Next Year
- WLGS N/A
- JAGX $39.96
- P/E Ratio
- WLGS $9.12
- JAGX N/A
- Revenue Growth
- WLGS 66.93
- JAGX 19.75
- 52 Week Low
- WLGS $0.15
- JAGX $4.02
- 52 Week High
- WLGS $9.66
- JAGX $502.50
- Technical
- Relative Strength Index (RSI)
- WLGS 28.36
- JAGX 46.54
- Support Level
- WLGS $0.15
- JAGX $10.41
- Resistance Level
- WLGS $0.19
- JAGX $13.20
- Average True Range (ATR)
- WLGS 0.02
- JAGX 1.90
- MACD
- WLGS 0.13
- JAGX 0.07
- Stochastic Oscillator
- WLGS 27.47
- JAGX 29.02
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.